Quarterly Period Covered: Q2 2026 (six months ended June 30, 2026) filed on July 30, 2026 Financial Statements Included: Unaudited consolidated balance sheets, statements of earnings, comprehensive income, cash flows, and statements of equity for the six-month and quarter-to-date periods in 2026 compared to 2025 Revenue Recognition Disclosures: Details on performance obligations with expected…

Our analysis rates this filing NEUTRAL. Baxter International presents a MODERATE concern profile appropriate for a stable, diversified healthcare company navigating a significant operational transition. The kidney care divestiture represents the most material change, shifting from owned operations…

Concern level: ELEVATED (5.2/10). Key factors: Kidney Care Business divestiture creates supply chain concentration risk - company now dependent on third-party manufacturer for previously owned revenue stream (severity 6/10); Environmental remediation liabilities at Superfund sites represent contingent obligations with potential for material future costs (severity 5/10); Active litigation matter…

Notable risk changes: Kidney Care divestiture completed with ongoing supply dependencies - company now relies on third-party manufacturer for previously owned business segment, creating supply chain concentration risk; Environmental remediation liabilities at Superfund sites disclosed as contingent obligation - potential for material future costs related to legacy operations; Active litigation matter (Novum LVP)…

The model predicts BAX will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.